ACXP Acurx Pharmaceuticals Inc

$ACXP pathfinder started on Aug 3, and they've enrolled one patient. 2 months per patient enrollment rate which tracks their prior enrollment performance. It is a 20 patient study. So this will take 40 months at this rate. In 2025 they burned $ 7M. In 2024 they burned $ 10M during clinical trials. They have $ 10M cash on hand. So they won't have enough cash to finish this open label, single arm study, and if they did, it would be in 3.5 years. Luci and Friends will get another year of salary. Maybe 1.5 years if they do another dilution. Either way they will get delisted for going under $1, or going under $ 5M market cap. That is coming in the next few months based on current trends. RIP Ibezapolstat. FU LUCI

$ACXP at .99 they can do a reverse split, but at 0.84 they fall under 5M market cap and will have to delist. at down 0.10 per week this thing should be delisted by mid November. Only thing that can stop it is real nondilutive funding such as a grant, funding through partnership, etc. With only 1 patient done in 2 months (out of 20 patients). The good news for Luci is that he can get delisted, and slow recruiting activities down to a crawl. This will cut recruiting costs, helping them to take their salaries longer. They only have about 10M in cash, which historically is about a year of runway. They can get another 5 or 6 patients enrolled in that time, or they can enroll one or two and stretch the cash out for 18+ months to pay themselves. They are in the endgame now. Luci and friends need to figure out how to squeeze as much cash as possible out of this desiccated corpse of a company. The shareholders will suffer. Science will suffer. Luci will profit.

$ACXP signed a 12-month media series with New to The Street to broadcast monthly interviews on its antibiotic pipeline.

$ACXP Back in April I predicted 3 patients enrolled by November. Well, they've only enrolled 1 patient by October. No way will he get 3 by November. And yet he will keep pretending until the music stops. Somehow Luci always finds a way to underdeliver. Hopefully he gets delisted sooner than later, before the cash is gone, so their remaining cash can go back to shareholders. FU Luci!

$ACXP looking for a position here. Looks like plague stocks might be good to get into right now.

$ACXP Buy shares in this "company" to fund the retirement accounts of the two old men who are the only employees. Where do you think the money from their quarterly offerings go? Help those poor old men afford their country club dues to help the stock avoid delisting.

$ACXP begins patient enrollment in its PATHFINDER Phase 2 trial of ibezapolstat for multiply-recurrent C. difficile infection.